LOS ANGELES and HOFFMAN ESTATES, Ill. - Siemens Medical Solutions has opened a new state-of-the-art research facility dedicated exclusively to the development of molecular imaging biomarkers, which will become in vivo diagnostic tools for identifying debilitating diseases such as cancer, and neurological diseases at their earliest stages.
The opening of the Siemens Medical Solutions Molecular Imaging (MI) Biomarker Research facility is the latest step for the company in becoming the world's first full-service diagnostics company, integrating in vivo and in vitro imaging diagnostics capabilities. Siemens recently launched Siemens Medical Solutions Diagnostics as the in vitro complement to the portfolio on the heels of acquisitions of Bayer Diagnostics and Los Angeles-based Diagnostic Products Corporation.
Story Continues Below Advertisement
Agfa HealthCare has taken a key role in understanding & contributing to best practices for dose management. Click here & learn how you can meet today's challenges while providing excellent productivity & quality patient care.
"Molecular medicine is heralding a new era in diagnostic capabilities that could change the lives of millions of Americans - and Siemens is helping lead the field out of the research lab and into practical use," said Michael Reitermann, president, Molecular Imaging division, Siemens Medical Solutions. "Advancing this field brings with it the promise of personalized therapeutics, which would not only improve the efficiency of health care, but most importantly, would also improve the quality of health care for patients."
Siemens Medical Solutions MI Biomarker Research facility will be dedicated solely to the discovery and development of new imaging biomarkers to spur the growth of in vivo molecular diagnostics. Imaging biomarkers are molecules that are specifically designed to seek out disease indicators that may appear in individual cells or tissue in the organism and that may provide early warning signs of disease. Once these imaging biomarkers bind to the diseased cells or tissues, they cause them to "light up" when scanned using PET (Positron Emission Tomography, CT(Computed Tomography) or SPECT(Single-Photon Emission Computed Tomography).
Imaging biomarkers not only enable early diagnosis, but also allow the measurement of how well certain therapies, such as prescription drugs, chemotherapy and radiation therapy, may be working by measuring the impact of treatments on the disease indicators. This may aid the development of new therapies, and enable clinicians to non-invasively assess therapeutic success and quickly adjust therapeutic approaches to arrive at optimum outcomes.
The new Siemens' facility will be led by Hartmuth Kolb, Ph.D, vice president, Siemens Medical Solutions MI Biomarker Research. The facility will house scientists, dedicated to the discovery of new imaging agents and their clinical development, with the goal of bringing several new agents to the market over the next 5 - 10 years. Research and development efforts conducted at the facility will focus largely on oncology and neurology, and also include other areas such as inflammation and microfluidics/nanotechnology research.
Continue reading Siemens Opens Research Facility for Molecular Imaging Biomarkers...